Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Lumasiran: Clinical Pharmacology
Standard Response Letter on lumasiran and its pharmacokinetic and pharmacodynamic properties.
Standard Response Letter on lumasiran and its pharmacokinetic and pharmacodynamic properties.
Vutrisiran: Cross-Reactivity with Patisiran
Standard response letter on the cross-reactivity between vutrisiran and patisiran.
Standard response letter on the cross-reactivity between vutrisiran and patisiran.
Zilebesiran: KARDIA-2 Study
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Vutrisiran: Storage and Stability
Standard response letter on vutrisiran and storage and stability. The letter contains information on product stability when stored at a range of temperatures, photostability, and thermal cycling.
Standard response letter on vutrisiran and storage and stability. The letter contains information on product stability when stored at a range of temperatures, photostability, and thermal cycling.
Patisiran: Total Dilution Volume
Standard response letter on patisiran and total dilution volume. This letter contains information on a stability study and the APOLLO, APOLLO-B, and Global OLE studies.
Standard response letter on patisiran and total dilution volume. This letter contains information on a stability study and the APOLLO, APOLLO-B, and Global OLE studies.
Patisiran: Half-Life and Duration of Effect
Standard response letter on the half-life and duration of effect of patisiran.
Standard response letter on the half-life and duration of effect of patisiran.
Vutrisiran: Autonomic Symptom Assessment
Standard Response Letter on vutrisiran and autonomic outcomes from the HELIOS-A study.
Standard Response Letter on vutrisiran and autonomic outcomes from the HELIOS-A study.
Patisiran: Cardiac Results from the Global OLE Study
Standard response letter on patisiran and cardiac results in the APOLLO OLE study, a study evaluating the long-term efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Standard response letter on patisiran and cardiac results in the APOLLO OLE study, a study evaluating the long-term efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Givosiran: Elevations in Blood Homocysteine
Standard response letter on givosiran and elevations in blood homocysteine.
Standard response letter on givosiran and elevations in blood homocysteine.
Vutrisiran: Immunogenicity
Standard response letter on vutrisiran and anti-drug antibodies. This letter contains information on the percentage of patients in vutrisiran clinical studies who tested positive for anti-drug antibodies.
Standard response letter on vutrisiran and anti-drug antibodies. This letter contains information on the percentage of patients in vutrisiran clinical studies who tested positive for anti-drug antibodies.
